- Home
- NUVL vs SIGI Comparison
NUVL vs SIGI Comparison
Compare NUVL & SIGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- SIGI
- Stock Information
- Founded
- NUVL 2017
- SIGI 1926
- Country
- NUVL United States
- SIGI United States
- Employees
- NUVL N/A
- SIGI N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- SIGI Property-Casualty Insurers
- Sector
- NUVL Health Care
- SIGI Finance
- Exchange
- NUVL Nasdaq
- SIGI Nasdaq
- Market Cap
- NUVL 5.6B
- SIGI 5.1B
- IPO Year
- NUVL 2021
- SIGI N/A
- Fundamental
- Price
- NUVL $73.48
- SIGI $87.57
- Analyst Decision
- NUVL Strong Buy
- SIGI Hold
- Analyst Count
- NUVL 8
- SIGI 8
- Target Price
- NUVL $115.50
- SIGI $95.17
- AVG Volume (30 Days)
- NUVL 682.1K
- SIGI 418.5K
- Earning Date
- NUVL 05-08-2025
- SIGI 04-23-2025
- Dividend Yield
- NUVL N/A
- SIGI 1.67%
- EPS Growth
- NUVL N/A
- SIGI N/A
- EPS
- NUVL N/A
- SIGI 3.68
- Revenue
- NUVL N/A
- SIGI $4,981,864,000.00
- Revenue This Year
- NUVL N/A
- SIGI $6.49
- Revenue Next Year
- NUVL N/A
- SIGI $7.69
- P/E Ratio
- NUVL N/A
- SIGI $24.81
- Revenue Growth
- NUVL N/A
- SIGI 13.29
- 52 Week Low
- NUVL $55.54
- SIGI $78.13
- 52 Week High
- NUVL $113.51
- SIGI $103.60
- Technical
- Relative Strength Index (RSI)
- NUVL 54.91
- SIGI 47.77
- Support Level
- NUVL $71.60
- SIGI $86.99
- Resistance Level
- NUVL $74.28
- SIGI $93.38
- Average True Range (ATR)
- NUVL 4.86
- SIGI 3.12
- MACD
- NUVL 1.08
- SIGI 0.04
- Stochastic Oscillator
- NUVL 95.73
- SIGI 52.99
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About SIGI Selective Insurance Group Inc.
Selective Insurance Group Inc is a regional property-casualty insurer based in New Jersey, with its operations focused in the New York metropolitan area. Since 1977, Selective has focused its sales efforts on small businesses, offering commercial products that include workers' compensation, general liability, property, and auto insurance. Selective also has a small personal insurance segment (under 20% of total premiums), selling auto and homeowner's coverage.